Your browser doesn't support javascript.
Treating the SARS-CoV-2-positive patient with cancer: A proposal for a pragmatic and transparent ethical process.
Perni, Subha; Milligan, Michael G; Saraf, Anurag; Vivenzio, Todd; Marques, Amy; Baker, Meghan A; Kosak, Tara; Bartlett, Sarah; Physic, Michelle A; Batchelder, Monica R; McBride, Sean; Bredfeldt, Jeremy; Cail, Daniel W; Kearney, Meghan C; Whitehouse, Colleen; Orio, Peter; Walsh, Gerard; Haas-Kogan, Daphne A; Martin, Neil E.
  • Perni S; Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts, USA.
  • Milligan MG; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Saraf A; Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts, USA.
  • Vivenzio T; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Marques A; Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts, USA.
  • Baker MA; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Kosak T; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Bartlett S; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Physic MA; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Batchelder MR; Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Harvard University, Boston, Massachusetts, USA.
  • McBride S; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Bredfeldt J; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Cail DW; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Kearney MC; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Whitehouse C; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Orio P; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Walsh G; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Haas-Kogan DA; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
  • Martin NE; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
Cancer ; 126(17): 3896-3899, 2020 09 01.
Article in English | MEDLINE | ID: covidwho-401377
ABSTRACT
The treatment of patients with cancer who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses unique challenges. In this commentary, the authors describe the ethical rationale and implementation details for the creation of a novel, multidisciplinary treatment prioritization committee, including physicians, frontline staff, an ethicist, and an infectious disease expert. Organizational obligations to health care workers also are discussed. The treatment prioritization committee sets a threshold of acceptable harm to patients from decreased cancer control that is justified to reduce risk to staff. The creation of an ethical, consistent, and transparent decision-making process involving such frontline stakeholders is essential as departments across the country are faced with decisions regarding the treatment of SARS-CoV-2-positive patients with cancer.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Quality of Health Care / Health Personnel / Coronavirus Infections / Delivery of Health Care / Pandemics / Betacoronavirus / Neoplasms Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Cancer Year: 2020 Document Type: Article Affiliation country: Cncr.32962

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Quality of Health Care / Health Personnel / Coronavirus Infections / Delivery of Health Care / Pandemics / Betacoronavirus / Neoplasms Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Cancer Year: 2020 Document Type: Article Affiliation country: Cncr.32962